| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 223 | 2024 | 2403 | 21.860 |
Why?
|
| Friedreich Ataxia | 57 | 2023 | 64 | 19.230 |
Why?
|
| Lung Diseases, Interstitial | 79 | 2024 | 469 | 12.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 89 | 2023 | 1114 | 10.650 |
Why?
|
| Pulmonary Emphysema | 62 | 2024 | 318 | 10.050 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 54 | 2024 | 453 | 8.580 |
Why?
|
| Lung | 129 | 2024 | 3588 | 6.910 |
Why?
|
| Iron-Binding Proteins | 29 | 2023 | 38 | 4.880 |
Why?
|
| Pulmonary Fibrosis | 27 | 2023 | 304 | 4.720 |
Why?
|
| Lung Diseases | 29 | 2023 | 693 | 4.430 |
Why?
|
| Smoking | 56 | 2023 | 1457 | 3.770 |
Why?
|
| Emphysema | 15 | 2024 | 123 | 3.630 |
Why?
|
| Humans | 408 | 2024 | 117051 | 2.910 |
Why?
|
| Radiography, Thoracic | 23 | 2023 | 161 | 2.900 |
Why?
|
| Lung Neoplasms | 28 | 2023 | 2222 | 2.600 |
Why?
|
| Alveolitis, Extrinsic Allergic | 13 | 2023 | 84 | 2.530 |
Why?
|
| Middle Aged | 189 | 2024 | 27172 | 2.480 |
Why?
|
| Idiopathic Interstitial Pneumonias | 14 | 2019 | 41 | 2.450 |
Why?
|
| Smokers | 16 | 2023 | 148 | 2.320 |
Why?
|
| Aged | 151 | 2024 | 19358 | 2.200 |
Why?
|
| Male | 227 | 2024 | 56663 | 2.090 |
Why?
|
| Diagnostic Imaging | 9 | 2022 | 294 | 2.030 |
Why?
|
| Severity of Illness Index | 48 | 2023 | 2633 | 1.980 |
Why?
|
| Female | 224 | 2024 | 60634 | 1.960 |
Why?
|
| Disease Progression | 47 | 2023 | 2467 | 1.910 |
Why?
|
| Pattern Recognition, Automated | 4 | 2018 | 73 | 1.900 |
Why?
|
| Biopsy | 27 | 2023 | 1056 | 1.870 |
Why?
|
| Trinucleotide Repeat Expansion | 12 | 2023 | 24 | 1.840 |
Why?
|
| Forced Expiratory Volume | 36 | 2023 | 517 | 1.820 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 9 | 2021 | 184 | 1.820 |
Why?
|
| Diagnosis, Differential | 39 | 2023 | 1341 | 1.610 |
Why?
|
| Mucin-5B | 10 | 2020 | 177 | 1.520 |
Why?
|
| Quality of Life | 23 | 2024 | 2374 | 1.490 |
Why?
|
| Connective Tissue Diseases | 9 | 2019 | 57 | 1.450 |
Why?
|
| Cohort Studies | 41 | 2024 | 5051 | 1.390 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 11 | 2017 | 108 | 1.380 |
Why?
|
| Bronchiectasis | 10 | 2024 | 107 | 1.380 |
Why?
|
| Respiratory Function Tests | 27 | 2021 | 523 | 1.380 |
Why?
|
| Vital Capacity | 24 | 2024 | 257 | 1.360 |
Why?
|
| Reproducibility of Results | 38 | 2024 | 2819 | 1.350 |
Why?
|
| Incidental Findings | 3 | 2021 | 78 | 1.340 |
Why?
|
| Adult | 98 | 2024 | 31003 | 1.280 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2023 | 3121 | 1.260 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2019 | 696 | 1.240 |
Why?
|
| Aged, 80 and over | 49 | 2021 | 6453 | 1.230 |
Why?
|
| Early Detection of Cancer | 9 | 2023 | 356 | 1.200 |
Why?
|
| Pulmonary Artery | 6 | 2021 | 1025 | 1.130 |
Why?
|
| Occupational Diseases | 5 | 2015 | 135 | 1.130 |
Why?
|
| Vision Disorders | 2 | 2020 | 130 | 1.070 |
Why?
|
| Respiratory System Abnormalities | 2 | 2022 | 13 | 1.050 |
Why?
|
| Schizophrenia | 4 | 2022 | 417 | 1.010 |
Why?
|
| Retrospective Studies | 51 | 2024 | 12825 | 1.010 |
Why?
|
| Spirometry | 24 | 2023 | 258 | 1.010 |
Why?
|
| Sinusitis | 3 | 2023 | 180 | 0.990 |
Why?
|
| Sarcoidosis | 2 | 2018 | 129 | 0.980 |
Why?
|
| Common Variable Immunodeficiency | 3 | 2018 | 27 | 0.980 |
Why?
|
| Sensitivity and Specificity | 24 | 2021 | 1740 | 0.960 |
Why?
|
| Predictive Value of Tests | 13 | 2024 | 1825 | 0.940 |
Why?
|
| Lymph Nodes | 2 | 2019 | 430 | 0.940 |
Why?
|
| Cystic Fibrosis | 8 | 2023 | 977 | 0.940 |
Why?
|
| Positron-Emission Tomography | 5 | 2018 | 295 | 0.940 |
Why?
|
| Paranasal Sinuses | 3 | 2023 | 68 | 0.930 |
Why?
|
| Trinucleotide Repeats | 5 | 2023 | 24 | 0.930 |
Why?
|
| Lung Injury | 2 | 2024 | 191 | 0.920 |
Why?
|
| Prognosis | 24 | 2024 | 3390 | 0.900 |
Why?
|
| Respiratory-Gated Imaging Techniques | 3 | 2017 | 8 | 0.890 |
Why?
|
| Triterpenes | 1 | 2023 | 17 | 0.880 |
Why?
|
| Linoleic Acid | 1 | 2022 | 41 | 0.860 |
Why?
|
| Anthracosis | 1 | 2022 | 4 | 0.830 |
Why?
|
| Young Adult | 27 | 2021 | 10675 | 0.820 |
Why?
|
| Pulmonary Diffusing Capacity | 10 | 2020 | 58 | 0.810 |
Why?
|
| Phenotype | 22 | 2023 | 2891 | 0.800 |
Why?
|
| Homeostasis | 2 | 2016 | 588 | 0.800 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2023 | 57 | 0.790 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2019 | 26 | 0.790 |
Why?
|
| Algorithms | 11 | 2024 | 1505 | 0.770 |
Why?
|
| Machine Learning | 9 | 2020 | 315 | 0.750 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 97 | 0.750 |
Why?
|
| Visual Acuity | 2 | 2020 | 268 | 0.740 |
Why?
|
| Case-Control Studies | 23 | 2020 | 3099 | 0.730 |
Why?
|
| Ataxia | 3 | 2023 | 36 | 0.730 |
Why?
|
| Calcinosis | 1 | 2022 | 256 | 0.720 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 2480 | 0.710 |
Why?
|
| Dyspnea | 5 | 2023 | 202 | 0.700 |
Why?
|
| Double-Blind Method | 13 | 2023 | 1670 | 0.690 |
Why?
|
| Cardiomyopathies | 3 | 2021 | 298 | 0.680 |
Why?
|
| Adolescent | 32 | 2021 | 18214 | 0.680 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2013 | 366 | 0.660 |
Why?
|
| Antioxidants | 2 | 2014 | 554 | 0.640 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2021 | 435 | 0.630 |
Why?
|
| Prospective Studies | 27 | 2024 | 6389 | 0.630 |
Why?
|
| Bronchitis, Chronic | 4 | 2023 | 20 | 0.620 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2017 | 13 | 0.610 |
Why?
|
| Collagen Diseases | 3 | 2012 | 6 | 0.610 |
Why?
|
| Neurons | 8 | 2018 | 1309 | 0.610 |
Why?
|
| Thoracic Diseases | 2 | 2015 | 13 | 0.610 |
Why?
|
| Occupational Exposure | 7 | 2020 | 272 | 0.600 |
Why?
|
| Risk Factors | 32 | 2021 | 8873 | 0.600 |
Why?
|
| Genotype | 13 | 2020 | 1854 | 0.590 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 595 | 0.580 |
Why?
|
| Mental Health Services | 1 | 2021 | 321 | 0.580 |
Why?
|
| Interdisciplinary Communication | 2 | 2016 | 179 | 0.580 |
Why?
|
| Calpain | 3 | 2007 | 54 | 0.570 |
Why?
|
| Interferon-gamma | 2 | 2019 | 732 | 0.570 |
Why?
|
| Immunoassay | 3 | 2014 | 99 | 0.570 |
Why?
|
| Observer Variation | 11 | 2021 | 307 | 0.560 |
Why?
|
| Bronchiolitis | 4 | 2015 | 82 | 0.560 |
Why?
|
| Biomarkers | 14 | 2023 | 3549 | 0.540 |
Why?
|
| Echocardiography | 4 | 2017 | 564 | 0.540 |
Why?
|
| Mitochondria | 4 | 2020 | 775 | 0.540 |
Why?
|
| Follow-Up Studies | 19 | 2023 | 4507 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2020 | 2227 | 0.530 |
Why?
|
| Mass Screening | 6 | 2023 | 1034 | 0.530 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 1 | 2015 | 1 | 0.530 |
Why?
|
| Telemedicine | 2 | 2021 | 669 | 0.530 |
Why?
|
| Asthma | 7 | 2023 | 2156 | 0.530 |
Why?
|
| Dendrites | 2 | 2018 | 85 | 0.530 |
Why?
|
| Antigens, Surface | 2 | 2015 | 151 | 0.530 |
Why?
|
| Genome-Wide Association Study | 12 | 2020 | 1314 | 0.520 |
Why?
|
| Child | 30 | 2024 | 18877 | 0.520 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 102 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 678 | 0.510 |
Why?
|
| Airway Remodeling | 7 | 2021 | 57 | 0.500 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 62 | 0.500 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 108 | 0.490 |
Why?
|
| Nerve Tissue Proteins | 6 | 2018 | 540 | 0.490 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 17 | 0.480 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2018 | 2038 | 0.480 |
Why?
|
| Mouth Mucosa | 2 | 2014 | 81 | 0.470 |
Why?
|
| Autoantibodies | 7 | 2015 | 1332 | 0.470 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2022 | 993 | 0.470 |
Why?
|
| Radiographic Image Enhancement | 5 | 2020 | 65 | 0.470 |
Why?
|
| Vascular Diseases | 2 | 2009 | 239 | 0.470 |
Why?
|
| Heterozygote | 5 | 2020 | 256 | 0.460 |
Why?
|
| Regression Analysis | 11 | 2019 | 971 | 0.460 |
Why?
|
| Polymorphism, Genetic | 4 | 2017 | 629 | 0.450 |
Why?
|
| Support Vector Machine | 1 | 2013 | 36 | 0.450 |
Why?
|
| Neuronal Plasticity | 3 | 2010 | 215 | 0.440 |
Why?
|
| Tomography, Spiral Computed | 4 | 2013 | 24 | 0.440 |
Why?
|
| Spinocerebellar Degenerations | 2 | 2023 | 5 | 0.440 |
Why?
|
| Cerebellar Ataxia | 2 | 2023 | 7 | 0.440 |
Why?
|
| United States | 32 | 2024 | 12380 | 0.440 |
Why?
|
| Sequence Analysis, RNA | 5 | 2018 | 407 | 0.430 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 44 | 0.430 |
Why?
|
| Receptor for Advanced Glycation End Products | 3 | 2022 | 32 | 0.430 |
Why?
|
| Health Status | 6 | 2023 | 726 | 0.430 |
Why?
|
| Angiography | 2 | 2013 | 179 | 0.430 |
Why?
|
| Cells, Cultured | 10 | 2021 | 3956 | 0.430 |
Why?
|
| Receptors, Nicotinic | 3 | 2015 | 270 | 0.420 |
Why?
|
| Heart Diseases | 2 | 2017 | 336 | 0.420 |
Why?
|
| Exhalation | 3 | 2018 | 35 | 0.420 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2023 | 79 | 0.410 |
Why?
|
| Vena Cava, Superior | 1 | 2012 | 21 | 0.410 |
Why?
|
| Risk Assessment | 8 | 2019 | 3021 | 0.400 |
Why?
|
| Point Mutation | 4 | 2014 | 225 | 0.400 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 81 | 0.400 |
Why?
|
| Osteosarcoma | 1 | 2012 | 66 | 0.400 |
Why?
|
| Troponin I | 1 | 2012 | 79 | 0.400 |
Why?
|
| Pandemics | 5 | 2024 | 1355 | 0.400 |
Why?
|
| Comorbidity | 9 | 2018 | 1487 | 0.400 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2022 | 289 | 0.390 |
Why?
|
| Rhinitis | 2 | 2023 | 133 | 0.390 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 93 | 0.390 |
Why?
|
| Glucose | 1 | 2016 | 931 | 0.390 |
Why?
|
| Genetic Variation | 4 | 2019 | 900 | 0.390 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 106 | 0.390 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2021 | 497 | 0.380 |
Why?
|
| Respiratory Tract Diseases | 3 | 2018 | 141 | 0.380 |
Why?
|
| Doxorubicin | 1 | 2012 | 294 | 0.380 |
Why?
|
| Pulmonary Embolism | 2 | 2012 | 180 | 0.370 |
Why?
|
| Heart Transplantation | 1 | 2017 | 661 | 0.370 |
Why?
|
| Databases, Factual | 2 | 2015 | 1167 | 0.370 |
Why?
|
| Ubiquinone | 1 | 2010 | 22 | 0.370 |
Why?
|
| Mutation | 7 | 2022 | 3420 | 0.370 |
Why?
|
| Mass Spectrometry | 6 | 2023 | 661 | 0.370 |
Why?
|
| Cysts | 3 | 2023 | 94 | 0.360 |
Why?
|
| Presynaptic Terminals | 1 | 2010 | 55 | 0.360 |
Why?
|
| Dysarthria | 1 | 2010 | 9 | 0.360 |
Why?
|
| Stroke Volume | 2 | 2017 | 514 | 0.360 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 195 | 0.360 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2020 | 218 | 0.360 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 328 | 0.360 |
Why?
|
| Survival Analysis | 7 | 2020 | 1240 | 0.360 |
Why?
|
| Radiation Dosage | 5 | 2022 | 143 | 0.350 |
Why?
|
| Encephalitis | 2 | 2008 | 127 | 0.350 |
Why?
|
| Pulmonary Atelectasis | 3 | 2018 | 12 | 0.350 |
Why?
|
| Multivariate Analysis | 10 | 2019 | 1458 | 0.340 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 2 | 2019 | 4 | 0.340 |
Why?
|
| Surveys and Questionnaires | 11 | 2021 | 4661 | 0.340 |
Why?
|
| Bronchi | 2 | 2024 | 241 | 0.330 |
Why?
|
| Gadolinium | 4 | 2020 | 79 | 0.330 |
Why?
|
| Chronic Disease | 8 | 2023 | 1619 | 0.330 |
Why?
|
| Fibroblasts | 6 | 2022 | 839 | 0.330 |
Why?
|
| Tomography, Emission-Computed | 2 | 2006 | 58 | 0.330 |
Why?
|
| ROC Curve | 5 | 2019 | 460 | 0.320 |
Why?
|
| Feasibility Studies | 4 | 2018 | 750 | 0.320 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2008 | 20 | 0.320 |
Why?
|
| Birt-Hogg-Dube Syndrome | 4 | 2023 | 6 | 0.320 |
Why?
|
| Bronchioles | 2 | 2019 | 22 | 0.320 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 4510 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 1403 | 0.310 |
Why?
|
| Sex Factors | 5 | 2018 | 1758 | 0.310 |
Why?
|
| Histiocytosis, Langerhans-Cell | 4 | 2023 | 35 | 0.310 |
Why?
|
| Body Mass Index | 7 | 2018 | 2070 | 0.310 |
Why?
|
| Linear Models | 8 | 2018 | 802 | 0.310 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 277 | 0.310 |
Why?
|
| Analysis of Variance | 5 | 2014 | 1239 | 0.300 |
Why?
|
| Pseudomonas Infections | 1 | 2009 | 192 | 0.300 |
Why?
|
| Nitrogen Dioxide | 1 | 2007 | 22 | 0.300 |
Why?
|
| Siblings | 1 | 2008 | 228 | 0.290 |
Why?
|
| Schizophrenic Psychology | 3 | 2022 | 86 | 0.290 |
Why?
|
| Radiology | 2 | 2014 | 198 | 0.290 |
Why?
|
| Respiration | 5 | 2023 | 182 | 0.290 |
Why?
|
| Consensus | 2 | 2023 | 532 | 0.290 |
Why?
|
| Nervous System Diseases | 2 | 2007 | 254 | 0.290 |
Why?
|
| Animals | 22 | 2021 | 32737 | 0.290 |
Why?
|
| Synapses | 2 | 2009 | 340 | 0.280 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2007 | 35 | 0.280 |
Why?
|
| Autoimmune Diseases | 2 | 2024 | 397 | 0.280 |
Why?
|
| Acute Disease | 6 | 2021 | 916 | 0.280 |
Why?
|
| Total Lung Capacity | 7 | 2020 | 32 | 0.280 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2023 | 78 | 0.280 |
Why?
|
| Neurologic Examination | 3 | 2012 | 118 | 0.280 |
Why?
|
| Bronchography | 3 | 2013 | 10 | 0.280 |
Why?
|
| Alleles | 6 | 2019 | 816 | 0.280 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2023 | 23 | 0.280 |
Why?
|
| Lung Volume Measurements | 3 | 2021 | 46 | 0.280 |
Why?
|
| Child, Preschool | 11 | 2019 | 9323 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2023 | 9257 | 0.270 |
Why?
|
| Walking | 3 | 2022 | 420 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 975 | 0.270 |
Why?
|
| Hypoxia | 1 | 2012 | 950 | 0.260 |
Why?
|
| Early Diagnosis | 5 | 2021 | 221 | 0.260 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 446 | 0.260 |
Why?
|
| Hippocampus | 3 | 2009 | 710 | 0.260 |
Why?
|
| Protein Subunits | 2 | 2021 | 207 | 0.250 |
Why?
|
| Mycobacterium Infections | 1 | 2005 | 61 | 0.250 |
Why?
|
| Airway Obstruction | 2 | 2019 | 165 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 686 | 0.250 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 350 | 0.250 |
Why?
|
| beta Catenin | 1 | 2007 | 223 | 0.250 |
Why?
|
| Protein Isoforms | 3 | 2019 | 345 | 0.250 |
Why?
|
| Olfaction Disorders | 2 | 2023 | 50 | 0.250 |
Why?
|
| Blood Glucose | 1 | 2014 | 1931 | 0.250 |
Why?
|
| Dopamine | 2 | 2006 | 240 | 0.250 |
Why?
|
| Logistic Models | 10 | 2018 | 1877 | 0.250 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 258 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 188 | 0.240 |
Why?
|
| Prevalence | 9 | 2023 | 2300 | 0.240 |
Why?
|
| Introns | 2 | 2023 | 228 | 0.240 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2016 | 25 | 0.240 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 280 | 0.230 |
Why?
|
| Survival Rate | 6 | 2018 | 1679 | 0.230 |
Why?
|
| Tropanes | 1 | 2003 | 3 | 0.230 |
Why?
|
| Cluster Analysis | 4 | 2019 | 478 | 0.230 |
Why?
|
| Patient Advocacy | 1 | 2024 | 65 | 0.230 |
Why?
|
| Incidence | 9 | 2023 | 2377 | 0.230 |
Why?
|
| Motivation | 3 | 2022 | 498 | 0.230 |
Why?
|
| Organotechnetium Compounds | 1 | 2003 | 17 | 0.230 |
Why?
|
| Mitochondrial Proteins | 2 | 2023 | 223 | 0.230 |
Why?
|
| Rats | 6 | 2015 | 5172 | 0.220 |
Why?
|
| Molecular Epidemiology | 2 | 2022 | 69 | 0.220 |
Why?
|
| Exercise Test | 4 | 2016 | 541 | 0.220 |
Why?
|
| Blotting, Western | 4 | 2019 | 1172 | 0.220 |
Why?
|
| International Cooperation | 4 | 2017 | 173 | 0.220 |
Why?
|
| Corpus Striatum | 2 | 2006 | 123 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2023 | 165 | 0.220 |
Why?
|
| Contrast Media | 3 | 2020 | 372 | 0.220 |
Why?
|
| Linoleic Acids | 1 | 2022 | 4 | 0.220 |
Why?
|
| Blood Platelets | 2 | 2018 | 328 | 0.220 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 439 | 0.220 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 101 | 0.220 |
Why?
|
| Age of Onset | 6 | 2019 | 456 | 0.220 |
Why?
|
| Smell | 1 | 2023 | 118 | 0.220 |
Why?
|
| Models, Biological | 4 | 2017 | 1689 | 0.210 |
Why?
|
| Clinical Trials as Topic | 6 | 2024 | 957 | 0.210 |
Why?
|
| Carcinogens, Environmental | 1 | 2002 | 6 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 5 | 2019 | 1141 | 0.210 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 930 | 0.210 |
Why?
|
| Asbestos | 1 | 2002 | 20 | 0.210 |
Why?
|
| Cerebral Cortex | 4 | 2018 | 392 | 0.210 |
Why?
|
| Ventricular Function | 2 | 2017 | 57 | 0.210 |
Why?
|
| Sjogren's Syndrome | 3 | 2019 | 40 | 0.210 |
Why?
|
| Antibodies | 2 | 2019 | 373 | 0.210 |
Why?
|
| Time Factors | 9 | 2020 | 6240 | 0.210 |
Why?
|
| Guanine | 3 | 2022 | 74 | 0.210 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 513 | 0.210 |
Why?
|
| Environmental Exposure | 4 | 2020 | 385 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 138 | 0.210 |
Why?
|
| Bleomycin | 3 | 2021 | 228 | 0.210 |
Why?
|
| Mesothelioma | 1 | 2002 | 31 | 0.210 |
Why?
|
| Hypertension, Pulmonary | 5 | 2021 | 1771 | 0.200 |
Why?
|
| Genetic Therapy | 2 | 2021 | 266 | 0.200 |
Why?
|
| Bronchial Diseases | 2 | 2012 | 34 | 0.200 |
Why?
|
| Fibrosis | 7 | 2022 | 478 | 0.200 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 94 | 0.200 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2017 | 18 | 0.200 |
Why?
|
| Cyclophosphamide | 3 | 2011 | 218 | 0.200 |
Why?
|
| Societies, Medical | 8 | 2021 | 684 | 0.200 |
Why?
|
| Carbon Monoxide | 3 | 2019 | 63 | 0.200 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 40 | 0.200 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 1105 | 0.200 |
Why?
|
| Retinoids | 1 | 2021 | 32 | 0.190 |
Why?
|
| Respiration Disorders | 1 | 2021 | 66 | 0.190 |
Why?
|
| Protein C | 1 | 2021 | 42 | 0.190 |
Why?
|
| Brain | 3 | 2020 | 2381 | 0.190 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2021 | 41 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 803 | 0.190 |
Why?
|
| Statistics as Topic | 4 | 2012 | 299 | 0.190 |
Why?
|
| Scleroderma, Systemic | 3 | 2019 | 94 | 0.190 |
Why?
|
| Bacteriophages | 1 | 2022 | 76 | 0.190 |
Why?
|
| RNA Stability | 1 | 2021 | 96 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 82 | 0.190 |
Why?
|
| Adenine | 3 | 2022 | 222 | 0.190 |
Why?
|
| DNA | 2 | 2018 | 1372 | 0.190 |
Why?
|
| RNA, Messenger | 5 | 2021 | 2632 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2021 | 55 | 0.180 |
Why?
|
| Mycobacterium abscessus | 1 | 2022 | 98 | 0.180 |
Why?
|
| Age Factors | 4 | 2015 | 2951 | 0.180 |
Why?
|
| Cognitive Remediation | 1 | 2020 | 1 | 0.180 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 1258 | 0.180 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2022 | 485 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2022 | 1394 | 0.180 |
Why?
|
| Intermediate Filaments | 1 | 2020 | 46 | 0.180 |
Why?
|
| Mice | 10 | 2021 | 15309 | 0.180 |
Why?
|
| Parkinson Disease | 2 | 2006 | 334 | 0.180 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 34 | 0.180 |
Why?
|
| Teratoma | 3 | 2010 | 91 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 4839 | 0.180 |
Why?
|
| Pulmonary Medicine | 3 | 2015 | 85 | 0.180 |
Why?
|
| Rare Diseases | 2 | 2018 | 91 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 191 | 0.180 |
Why?
|
| Vasoconstriction | 1 | 2021 | 201 | 0.170 |
Why?
|
| Health Resources | 1 | 2021 | 129 | 0.170 |
Why?
|
| Sensorimotor Cortex | 1 | 2019 | 2 | 0.170 |
Why?
|
| Desmoplakins | 1 | 2019 | 19 | 0.170 |
Why?
|
| Hyperostosis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Afferent Pathways | 1 | 2019 | 43 | 0.170 |
Why?
|
| DiGeorge Syndrome | 2 | 2012 | 20 | 0.170 |
Why?
|
| Cigarette Smoking | 2 | 2020 | 80 | 0.170 |
Why?
|
| Chromatography, Liquid | 3 | 2018 | 350 | 0.170 |
Why?
|
| Genetic Markers | 3 | 2021 | 338 | 0.170 |
Why?
|
| Proprioception | 1 | 2019 | 18 | 0.170 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2021 | 234 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 212 | 0.170 |
Why?
|
| Indoles | 2 | 2019 | 311 | 0.170 |
Why?
|
| Racemases and Epimerases | 1 | 2018 | 11 | 0.170 |
Why?
|
| Psychometrics | 1 | 2022 | 602 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 1233 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sex Distribution | 5 | 2016 | 331 | 0.160 |
Why?
|
| Iron Regulatory Protein 2 | 2 | 2015 | 7 | 0.160 |
Why?
|
| Oral Hygiene | 1 | 2018 | 17 | 0.160 |
Why?
|
| Cause of Death | 2 | 2018 | 369 | 0.160 |
Why?
|
| Scleroderma, Limited | 2 | 2008 | 3 | 0.160 |
Why?
|
| Models, Theoretical | 2 | 2020 | 534 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2015 | 1040 | 0.160 |
Why?
|
| Genetic Loci | 3 | 2016 | 279 | 0.160 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2018 | 22 | 0.160 |
Why?
|
| Air Pollutants, Occupational | 1 | 2018 | 29 | 0.160 |
Why?
|
| Apolipoprotein A-I | 1 | 2018 | 24 | 0.160 |
Why?
|
| Self-Help Devices | 1 | 2018 | 19 | 0.160 |
Why?
|
| Carrier Proteins | 3 | 2015 | 719 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 243 | 0.160 |
Why?
|
| Fatigue | 1 | 2019 | 288 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 354 | 0.150 |
Why?
|
| Traction | 3 | 2023 | 18 | 0.150 |
Why?
|
| Societies | 1 | 2017 | 41 | 0.150 |
Why?
|
| Genomic Instability | 1 | 2017 | 38 | 0.150 |
Why?
|
| Respiratory System | 2 | 2016 | 141 | 0.150 |
Why?
|
| Pleura | 2 | 2015 | 18 | 0.150 |
Why?
|
| Premature Birth | 2 | 2012 | 276 | 0.150 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2009 | 17 | 0.150 |
Why?
|
| Spine | 1 | 2019 | 141 | 0.150 |
Why?
|
| Vascular Calcification | 1 | 2019 | 117 | 0.150 |
Why?
|
| Cardiac Volume | 1 | 2017 | 12 | 0.150 |
Why?
|
| Motion | 1 | 2017 | 95 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2022 | 337 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 181 | 0.150 |
Why?
|
| Nursing Homes | 1 | 2018 | 131 | 0.150 |
Why?
|
| Parenchymal Tissue | 1 | 2016 | 6 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 93 | 0.140 |
Why?
|
| Bayes Theorem | 2 | 2022 | 341 | 0.140 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2009 | 63 | 0.140 |
Why?
|
| Pneumonia | 4 | 2013 | 575 | 0.140 |
Why?
|
| Complement C3 | 1 | 2018 | 191 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 682 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 238 | 0.140 |
Why?
|
| Calibration | 1 | 2017 | 132 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2021 | 827 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 327 | 0.140 |
Why?
|
| Creatine | 1 | 2016 | 52 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2021 | 640 | 0.140 |
Why?
|
| Mucociliary Clearance | 1 | 2016 | 42 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2021 | 145 | 0.140 |
Why?
|
| Software Validation | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pulmonary Alveoli | 2 | 2016 | 373 | 0.140 |
Why?
|
| Arthritis, Experimental | 1 | 2018 | 133 | 0.140 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.140 |
Why?
|
| Respiratory Insufficiency | 2 | 2017 | 286 | 0.140 |
Why?
|
| Republic of Korea | 3 | 2023 | 26 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 40 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 79 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2015 | 26 | 0.130 |
Why?
|
| Tracheal Diseases | 1 | 2016 | 15 | 0.130 |
Why?
|
| Genomics | 1 | 2021 | 658 | 0.130 |
Why?
|
| Reference Values | 3 | 2013 | 751 | 0.130 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 97 | 0.130 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 157 | 0.130 |
Why?
|
| Occupational Health | 1 | 2018 | 172 | 0.130 |
Why?
|
| Pleural Diseases | 1 | 2015 | 21 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2011 | 1207 | 0.130 |
Why?
|
| Guanylate Kinases | 1 | 2015 | 13 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 284 | 0.130 |
Why?
|
| ELAV Proteins | 1 | 2015 | 17 | 0.130 |
Why?
|
| Electrocardiography | 3 | 2017 | 548 | 0.130 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2015 | 16 | 0.130 |
Why?
|
| Collagen | 1 | 2018 | 423 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 248 | 0.130 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 57 | 0.130 |
Why?
|
| Azathioprine | 1 | 2015 | 51 | 0.130 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 389 | 0.130 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 2408 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2021 | 940 | 0.130 |
Why?
|
| Interferon-beta | 2 | 2008 | 82 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 486 | 0.130 |
Why?
|
| Proteomics | 2 | 2021 | 844 | 0.130 |
Why?
|
| Galactosylceramidase | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cerebellum | 2 | 2015 | 202 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 794 | 0.130 |
Why?
|
| Transcriptome | 2 | 2018 | 756 | 0.130 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 362 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 667 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2016 | 97 | 0.130 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 92 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 131 | 0.130 |
Why?
|
| Physicians | 2 | 2022 | 781 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 158 | 0.120 |
Why?
|
| Axonemal Dyneins | 1 | 2014 | 8 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2015 | 176 | 0.120 |
Why?
|
| Brain Stem | 1 | 2015 | 102 | 0.120 |
Why?
|
| Military Personnel | 1 | 2022 | 532 | 0.120 |
Why?
|
| Prednisone | 1 | 2015 | 233 | 0.120 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 218 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 825 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 332 | 0.120 |
Why?
|
| Tyrosine | 2 | 2005 | 220 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2004 | 16 | 0.120 |
Why?
|
| Immunosuppressive Agents | 3 | 2015 | 674 | 0.120 |
Why?
|
| Myocardium | 1 | 2019 | 944 | 0.120 |
Why?
|
| Mass Chest X-Ray | 2 | 2010 | 4 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2015 | 81 | 0.120 |
Why?
|
| Age Distribution | 3 | 2016 | 340 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 3 | 2019 | 26 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1374 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1889 | 0.110 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 12 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2018 | 604 | 0.110 |
Why?
|
| Anisotropy | 1 | 2013 | 63 | 0.110 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2013 | 23 | 0.110 |
Why?
|
| Liver | 2 | 2020 | 1744 | 0.110 |
Why?
|
| Protons | 1 | 2013 | 77 | 0.110 |
Why?
|
| Inflammation | 4 | 2018 | 2515 | 0.110 |
Why?
|
| Heart Ventricles | 2 | 2017 | 728 | 0.110 |
Why?
|
| Research Design | 3 | 2022 | 962 | 0.110 |
Why?
|
| Qc-SNARE Proteins | 1 | 2012 | 7 | 0.110 |
Why?
|
| Qb-SNARE Proteins | 1 | 2012 | 6 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 639 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 56 | 0.110 |
Why?
|
| Elastic Modulus | 1 | 2013 | 118 | 0.110 |
Why?
|
| Iopamidol | 1 | 2012 | 13 | 0.110 |
Why?
|
| Fasting | 1 | 2014 | 251 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 172 | 0.110 |
Why?
|
| Blood Cells | 1 | 2012 | 39 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2020 | 899 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 381 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 127 | 0.100 |
Why?
|
| Ventricular Dysfunction | 1 | 2012 | 15 | 0.100 |
Why?
|
| Dextrocardia | 1 | 2012 | 3 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 230 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 3648 | 0.100 |
Why?
|
| Cilia | 1 | 2013 | 161 | 0.100 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 2 | 2008 | 8 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 115 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 184 | 0.100 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 441 | 0.100 |
Why?
|
| Sarcoma, Kaposi | 1 | 2012 | 69 | 0.100 |
Why?
|
| Diastole | 1 | 2011 | 142 | 0.100 |
Why?
|
| Bone Density | 1 | 2015 | 444 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 520 | 0.100 |
Why?
|
| Heart Atria | 1 | 2012 | 110 | 0.100 |
Why?
|
| Methotrexate | 1 | 2012 | 229 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2012 | 138 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2022 | 57 | 0.090 |
Why?
|
| Miniature Postsynaptic Potentials | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cell Line | 3 | 2016 | 2670 | 0.090 |
Why?
|
| Cisplatin | 1 | 2012 | 272 | 0.090 |
Why?
|
| Bronchoscopy | 3 | 2021 | 244 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2011 | 138 | 0.090 |
Why?
|
| Apgar Score | 1 | 2010 | 16 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2012 | 118 | 0.090 |
Why?
|
| Term Birth | 1 | 2010 | 19 | 0.090 |
Why?
|
| Aminophenols | 2 | 2022 | 115 | 0.090 |
Why?
|
| Leg | 1 | 2012 | 228 | 0.090 |
Why?
|
| Live Birth | 1 | 2010 | 48 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2012 | 260 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 250 | 0.090 |
Why?
|
| Hemoptysis | 1 | 2010 | 36 | 0.090 |
Why?
|
| Registries | 2 | 2017 | 1788 | 0.090 |
Why?
|
| Speech Disorders | 1 | 2010 | 32 | 0.090 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 91 | 0.090 |
Why?
|
| Aorta | 1 | 2012 | 358 | 0.090 |
Why?
|
| Scleroderma, Localized | 1 | 2009 | 7 | 0.090 |
Why?
|
| Walk Test | 2 | 2021 | 51 | 0.090 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2010 | 101 | 0.090 |
Why?
|
| Polymyositis | 1 | 2009 | 14 | 0.090 |
Why?
|
| Infant | 4 | 2019 | 8122 | 0.090 |
Why?
|
| Autoimmunity | 2 | 2015 | 829 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 268 | 0.090 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 245 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 566 | 0.090 |
Why?
|
| Survivors | 1 | 2013 | 408 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1588 | 0.090 |
Why?
|
| Exercise Tolerance | 3 | 2016 | 227 | 0.090 |
Why?
|
| X-Ray Microtomography | 2 | 2021 | 79 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2006 | 39 | 0.090 |
Why?
|
| Salivary Glands, Minor | 1 | 2009 | 6 | 0.090 |
Why?
|
| Abortion, Spontaneous | 1 | 2010 | 94 | 0.090 |
Why?
|
| Limbic Encephalitis | 1 | 2009 | 3 | 0.090 |
Why?
|
| alpha-Synuclein | 2 | 2006 | 29 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 1 | 2009 | 56 | 0.080 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2009 | 25 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 2010 | 120 | 0.080 |
Why?
|
| Speech | 1 | 2010 | 75 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 837 | 0.080 |
Why?
|
| Autoantigens | 2 | 2009 | 397 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2009 | 43 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2011 | 273 | 0.080 |
Why?
|
| Neurocognitive Disorders | 1 | 2008 | 23 | 0.080 |
Why?
|
| Axons | 1 | 2010 | 182 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2016 | 129 | 0.080 |
Why?
|
| Hospitalization | 2 | 2014 | 1762 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 185 | 0.080 |
Why?
|
| Scleroderma, Diffuse | 1 | 2008 | 4 | 0.080 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 18 | 0.080 |
Why?
|
| Calcium Signaling | 1 | 2010 | 215 | 0.080 |
Why?
|
| Insulin | 3 | 2014 | 2135 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 232 | 0.080 |
Why?
|
| Radiography | 4 | 2004 | 843 | 0.080 |
Why?
|
| Europe | 3 | 2015 | 349 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 339 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1144 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 282 | 0.080 |
Why?
|
| Receptors, AMPA | 1 | 2009 | 121 | 0.080 |
Why?
|
| Neurotoxins | 1 | 2007 | 25 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2024 | 107 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2007 | 54 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2012 | 512 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2011 | 451 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 434 | 0.070 |
Why?
|
| Community Medicine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 348 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2018 | 285 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2016 | 1590 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 1499 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 2010 | 416 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 222 | 0.070 |
Why?
|
| Birth Weight | 1 | 2010 | 466 | 0.070 |
Why?
|
| Pericardium | 1 | 2007 | 49 | 0.070 |
Why?
|
| Japan | 2 | 2021 | 96 | 0.070 |
Why?
|
| Pneumonectomy | 2 | 2023 | 126 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 106 | 0.070 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2006 | 14 | 0.070 |
Why?
|
| Epitopes | 1 | 2008 | 436 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 392 | 0.070 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2006 | 26 | 0.070 |
Why?
|
| Internationality | 2 | 2017 | 149 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1941 | 0.070 |
Why?
|
| United Kingdom | 2 | 2019 | 233 | 0.070 |
Why?
|
| Cytosol | 1 | 2006 | 206 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2006 | 79 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2018 | 626 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 627 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 455 | 0.070 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 171 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 642 | 0.070 |
Why?
|
| Conotoxins | 1 | 2005 | 4 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 610 | 0.070 |
Why?
|
| Cognition | 2 | 2021 | 988 | 0.070 |
Why?
|
| Organ Size | 2 | 2016 | 459 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 989 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 2032 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 1 | 2006 | 108 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2019 | 322 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2005 | 88 | 0.060 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2004 | 15 | 0.060 |
Why?
|
| Calcineurin | 1 | 2005 | 91 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 764 | 0.060 |
Why?
|
| Epilepsy | 1 | 2008 | 291 | 0.060 |
Why?
|
| Nitrates | 1 | 2004 | 74 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2004 | 114 | 0.060 |
Why?
|
| Immunoprecipitation | 2 | 2018 | 160 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 235 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 415 | 0.060 |
Why?
|
| Granuloma | 1 | 2004 | 84 | 0.060 |
Why?
|
| Ventricular Function, Right | 1 | 2006 | 261 | 0.060 |
Why?
|
| Smoking Cessation | 2 | 2018 | 357 | 0.060 |
Why?
|
| Residual Volume | 1 | 2023 | 6 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 299 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2019 | 273 | 0.060 |
Why?
|
| Monoamine Oxidase | 1 | 2003 | 27 | 0.060 |
Why?
|
| Textile Industry | 1 | 2003 | 1 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 404 | 0.060 |
Why?
|
| Minisatellite Repeats | 1 | 2003 | 38 | 0.060 |
Why?
|
| Tomography | 1 | 2023 | 21 | 0.060 |
Why?
|
| Gene Expression | 3 | 2017 | 1466 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2005 | 793 | 0.060 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 40 | 0.060 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2016 | 188 | 0.060 |
Why?
|
| Chloride Channel Agonists | 1 | 2023 | 62 | 0.060 |
Why?
|
| Unsupervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2023 | 53 | 0.050 |
Why?
|
| Coenzyme A | 1 | 2022 | 6 | 0.050 |
Why?
|
| Phosphatidylglycerols | 1 | 2022 | 20 | 0.050 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 17 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1782 | 0.050 |
Why?
|
| Antacids | 1 | 2022 | 15 | 0.050 |
Why?
|
| Lymphocytes | 2 | 2017 | 340 | 0.050 |
Why?
|
| Silicosis | 1 | 2002 | 21 | 0.050 |
Why?
|
| Sulfur | 1 | 2022 | 44 | 0.050 |
Why?
|
| Carnitine | 1 | 2022 | 65 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2002 | 32 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 114 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 408 | 0.050 |
Why?
|
| Oxygen | 2 | 2023 | 828 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 96 | 0.050 |
Why?
|
| Australia | 1 | 2022 | 209 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1730 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2021 | 52 | 0.050 |
Why?
|
| Pulmonologists | 1 | 2021 | 15 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 169 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2002 | 169 | 0.050 |
Why?
|
| Probability | 1 | 2022 | 296 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2004 | 264 | 0.050 |
Why?
|
| Research | 1 | 2005 | 402 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2022 | 147 | 0.050 |
Why?
|
| Belgium | 1 | 2021 | 9 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 99 | 0.050 |
Why?
|
| Poland | 1 | 2021 | 27 | 0.050 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2021 | 32 | 0.050 |
Why?
|
| Spain | 1 | 2021 | 34 | 0.050 |
Why?
|
| Sweden | 1 | 2021 | 63 | 0.050 |
Why?
|
| Radiologists | 1 | 2021 | 38 | 0.050 |
Why?
|
| Fractals | 1 | 2021 | 6 | 0.050 |
Why?
|
| Finland | 1 | 2021 | 70 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2021 | 140 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 88 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2021 | 62 | 0.050 |
Why?
|
| Germany | 1 | 2021 | 89 | 0.050 |
Why?
|
| New York | 1 | 2021 | 112 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1327 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 924 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2021 | 79 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2021 | 982 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 242 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2011 | 68 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 90 | 0.050 |
Why?
|
| Iceland | 1 | 2020 | 6 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2021 | 78 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 1001 | 0.050 |
Why?
|
| Mortality | 1 | 2002 | 291 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 500 | 0.040 |
Why?
|
| Air | 1 | 2020 | 37 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 741 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 337 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 6 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2014 | 228 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 188 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2010 | 5170 | 0.040 |
Why?
|
| Acrylamides | 1 | 2019 | 43 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 72 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2020 | 178 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 25 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 179 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2019 | 334 | 0.040 |
Why?
|
| Dermatomyositis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Histones | 2 | 2015 | 544 | 0.040 |
Why?
|
| Magnetoencephalography | 1 | 2019 | 104 | 0.040 |
Why?
|
| Iowa | 1 | 2018 | 25 | 0.040 |
Why?
|
| Colorado | 2 | 2019 | 4121 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 171 | 0.040 |
Why?
|
| Fingers | 1 | 2019 | 80 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2022 | 379 | 0.040 |
Why?
|
| Dental Hygienists | 1 | 2018 | 15 | 0.040 |
Why?
|
| Job Description | 1 | 2018 | 10 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 337 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 331 | 0.040 |
Why?
|
| Heart Failure | 1 | 2011 | 1962 | 0.040 |
Why?
|
| Pregnancy | 1 | 2010 | 5653 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 51 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 148 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 213 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 72 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 561 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 261 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2017 | 48 | 0.040 |
Why?
|
| Simvastatin | 1 | 2018 | 61 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2019 | 261 | 0.040 |
Why?
|
| Rheumatology | 1 | 2019 | 89 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 207 | 0.040 |
Why?
|
| Netherlands | 1 | 2017 | 65 | 0.040 |
Why?
|
| Death Certificates | 1 | 2017 | 27 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 255 | 0.040 |
Why?
|
| Syndrome | 2 | 2009 | 339 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2007 | 4606 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 335 | 0.040 |
Why?
|
| Phosphocreatine | 1 | 2016 | 37 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 878 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 656 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 623 | 0.030 |
Why?
|
| Uncertainty | 1 | 2017 | 98 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2017 | 92 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 2016 | 14 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2016 | 36 | 0.030 |
Why?
|
| Papilloma | 1 | 2016 | 45 | 0.030 |
Why?
|
| Tracheal Neoplasms | 1 | 2016 | 12 | 0.030 |
Why?
|
| Victoria | 1 | 2016 | 15 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 45 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 139 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 255 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Inhalation | 1 | 2016 | 25 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2019 | 569 | 0.030 |
Why?
|
| Asbestosis | 1 | 2015 | 13 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 2017 | 156 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 161 | 0.030 |
Why?
|
| Xenon Isotopes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Helium | 1 | 2015 | 7 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2016 | 62 | 0.030 |
Why?
|
| Fluorine | 1 | 2015 | 14 | 0.030 |
Why?
|
| Software | 1 | 2020 | 557 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mitochondria, Muscle | 1 | 2016 | 97 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Isotopes | 1 | 2015 | 26 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 268 | 0.030 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 36 | 0.030 |
Why?
|
| Transfection | 2 | 2009 | 877 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 572 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 967 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 118 | 0.030 |
Why?
|
| Aconitate Hydratase | 1 | 2015 | 17 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 103 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 226 | 0.030 |
Why?
|
| K562 Cells | 1 | 2015 | 73 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2015 | 46 | 0.030 |
Why?
|
| Perfusion | 1 | 2015 | 150 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 157 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2014 | 33 | 0.030 |
Why?
|
| Endodeoxyribonucleases | 1 | 2015 | 60 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 253 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 540 | 0.030 |
Why?
|
| Hemochromatosis Protein | 1 | 2014 | 3 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 228 | 0.030 |
Why?
|
| Mexico | 1 | 2014 | 164 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 82 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 34 | 0.030 |
Why?
|
| Nitrogen Isotopes | 1 | 2013 | 55 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 903 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 687 | 0.030 |
Why?
|
| Esters | 1 | 2013 | 61 | 0.030 |
Why?
|
| Carbon Isotopes | 1 | 2013 | 115 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 91 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2013 | 74 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2014 | 144 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 278 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 286 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 40 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1053 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 174 | 0.030 |
Why?
|
| APACHE | 1 | 2013 | 60 | 0.030 |
Why?
|
| Swine | 1 | 2015 | 714 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 1500 | 0.030 |
Why?
|
| Health Services | 1 | 2013 | 108 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2012 | 22 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 48 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 965 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 53 | 0.030 |
Why?
|
| Aortography | 1 | 2012 | 51 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 560 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 112 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2013 | 204 | 0.030 |
Why?
|
| Neoplasms | 2 | 2021 | 2146 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2012 | 8 | 0.030 |
Why?
|
| Arthrography | 1 | 2011 | 22 | 0.030 |
Why?
|
| Graves Disease | 1 | 2012 | 32 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 98 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2012 | 66 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2012 | 102 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2012 | 64 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 981 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 177 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 507 | 0.020 |
Why?
|
| Exome | 1 | 2012 | 209 | 0.020 |
Why?
|
| Pedigree | 1 | 2013 | 475 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 498 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 2648 | 0.020 |
Why?
|
| Education | 1 | 2012 | 101 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2011 | 54 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 142 | 0.020 |
Why?
|
| Joints | 1 | 2011 | 84 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 326 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2015 | 544 | 0.020 |
Why?
|
| Latin America | 1 | 2011 | 70 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 761 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 104 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 147 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 103 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2012 | 212 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 83 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 2814 | 0.020 |
Why?
|
| Alanine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
|
| Threonine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 198 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 744 | 0.020 |
Why?
|
| Minority Groups | 1 | 2010 | 233 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 630 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2008 | 15 | 0.020 |
Why?
|
| Specialization | 1 | 2009 | 115 | 0.020 |
Why?
|
| Apelin Receptors | 1 | 2007 | 4 | 0.020 |
Why?
|
| Apelin | 1 | 2007 | 9 | 0.020 |
Why?
|
| raf Kinases | 1 | 2007 | 11 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 546 | 0.020 |
Why?
|
| RNA | 1 | 2013 | 827 | 0.020 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2006 | 10 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2006 | 17 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 64 | 0.020 |
Why?
|
| Catechols | 1 | 2006 | 16 | 0.020 |
Why?
|
| Levodopa | 1 | 2006 | 23 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 159 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2006 | 41 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2006 | 68 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 804 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 256 | 0.020 |
Why?
|
| Parkinsonian Disorders | 1 | 2006 | 27 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 527 | 0.020 |
Why?
|
| Drug Industry | 1 | 2007 | 104 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 232 | 0.020 |
Why?
|
| Cell Death | 1 | 2007 | 333 | 0.020 |
Why?
|
| Tretinoin | 1 | 2006 | 115 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 187 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 159 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2006 | 131 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 350 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 1179 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 406 | 0.020 |
Why?
|
| Skin | 1 | 2009 | 655 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2004 | 12 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2006 | 166 | 0.020 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2004 | 13 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2009 | 491 | 0.020 |
Why?
|
| Synucleins | 1 | 2004 | 5 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2006 | 299 | 0.020 |
Why?
|
| Valine | 1 | 2004 | 75 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 1030 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 308 | 0.010 |
Why?
|
| Receptors, GABA-A | 1 | 2004 | 88 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 139 | 0.010 |
Why?
|
| Methionine | 1 | 2004 | 145 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 646 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 591 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 833 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 910 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 630 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 161 | 0.010 |
Why?
|
| Communication | 1 | 2009 | 759 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 249 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 936 | 0.010 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2002 | 2 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2321 | 0.010 |
Why?
|
| HIV-1 | 1 | 2007 | 771 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 467 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1993 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1949 | 0.010 |
Why?
|